Washington Just Paved the Way for America’s Next Copper Giant

When the White House cuts a check and clears a road, traders take notice.

The Trump administration’s new stake and infrastructure approval could turn this once-forgotten miner into a cornerstone of America’s critical minerals push.

The question now: how much higher can it dig?

Every giant starts small.

Tesla once traded for just a few dollars. Enphase was a penny stock. Now they are worth billions because they were early in an industry about to explode.

Energy storage is the next boom. By 2030, the US market is projected at $465 billion, a 75% surge from today’s $265 billion. Electricity prices are rising too, up 6.5% since 2024, with some states warning of 30% to 60% hikes.

This is not a problem going away. It is a megatrend only getting stronger.

And sitting right in the middle is a small US company that nobody talks about. Market cap? Just $177 million. Growth? More than 200% revenue expansion year over year. Institutional ownership is already over 30%. And government-backed projects proving the model in the field.

The best part? Trump’s new tariffs. Rivals could face 34% penalties on imported batteries. Enphase already admitted it will hit margins. This small stock avoids the squeeze thanks to its US and Austrian supply chain.

This is the setup investors dream about. A tiny stock in a $465 billion industry, with triple-digit growth and the billionaires already betting big on the sector.

See the full story before the crowd catches on.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Wall Street closed lower today as tech shares cooled after Oracle’s cloud-margin concerns triggered profit-taking in the sector following Monday’s AI-fueled rally.

The Ghost That Won’t Go Away

Johnson & Johnson (NYSE: JNJ) just got slapped with a $966 million verdict in California over its talc-based products — a ruling that instantly reignites one of the most stubborn controversies in corporate America.

The company plans to appeal, but you can already feel the tremor rippling through investor circles.

For years, J&J has tried to pivot away from the talc saga with spinoffs, settlements, and a massive restructuring.

But this verdict reminds everyone that old battles can still hijack new strategies. You might call it legal déjà vu — the kind that can rattle even a $400 billion titan.

The Money and the Message

Nearly a billion dollars isn’t pocket change, even for J&J. It means more legal reserves, tighter budgets, and less room for stock buybacks.

And just as the company is pumping cash into its drug and MedTech pipelines, that courtroom loss adds another weight to carry.

You can see why investors are uneasy. A few more verdicts like this, and the “safe dividend stock” image starts to crack under pressure.

A Reputation With Scars

J&J has built its empire on trust: baby powder, Band-Aids, and bulletproof earnings. But trust gets pricey when legacy issues refuse to fade.

The company’s real challenge now isn’t the payout; it’s reclaiming confidence in its brand story.

Because when a century-old name like J&J keeps showing up in courtrooms, even the most loyal shareholders start to wonder how clean the future really looks.

For J&J, healing consumers was always the business, but now it’s the balance sheet that needs a little recovery time.

Kellanova (NYSE: K), the home of Pringles, Pop-Tarts, and Kellogg’s cereals, is about to become part of the Mars galaxy.

The EU is set to approve the $36 billion deal without conditions, giving Mars the keys to one of the world’s most powerful snacking portfolios.

If you’re picturing M&M’s and Pringles under one roof, you’re not wrong.

Mars is taking its candy empire and giving it a salty sidekick, setting the stage for global snack domination.

With U.S. regulators already on board, this is as close to a done deal as it gets.

Why This Changes the Snack Game

For Kellanova, this merger is all about speed.

Mars’ global muscle means Pringles can pop up in more markets, Pop-Tarts can ride e-commerce waves, and Kellogg’s can get a branding refresh in places where cereal still feels premium.

You can expect new mashups, bigger marketing budgets, and a faster push into convenience and digital grocery channels.

Basically, more snacks in more hands, faster than ever.

What’s Next for the Snack Superpower

Yes, Kellanova loses its independence, but under Mars, its brands get a ticket to the big leagues.

The merger also signals a bigger shift in Big Food: consolidation is back, and growth is now about owning every bite of your day, from breakfast bowls to midnight cravings.

Forget breakfast versus dessert. Mars and Kellanova just built the world’s most tempting one-stop snack shop, and your pantry is next.

On Behalf of Pangea Natural Foods

Sometimes what drives a stock isn’t the size of the company.
It’s the size of the float.

This story is no different. A Canadian wellness innovator with fewer than 30 million shares available for trading is developing needle-free peptide products at exactly the right time.

That scarcity matters. Because when momentum meets limited supply, the price can move quickly.

What’s fueling demand?

Science-backed compounds called peptides. Once confined to syringes and elite clinics, they’re now being delivered in simple capsules, creams, and patches. It’s a shift that makes peptides accessible to millions of consumers for the first time.

The market already proved its appetite. Novo Nordisk and Eli Lilly turned peptide therapies like Ozempic into hundreds of billions in market value. Smaller players like Zealand Pharma and Rhythm climbed from micro-caps into multi-billion valuations.

But here’s the difference. Those giants are tied to needles, prescriptions, and clinical pipelines. This company is going straight to the consumer with needle-free delivery.

It owns the manufacturing. It controls the formulations. It’s already online with sales and exposure at major health expos.

And with such a small float, any spike in interest could magnify fast.

The setup is rare. The timing is now.

Unlock the full report right here.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

General Dynamics (NYSE: GD) just hit a fresh record above $340, powered by a wave of juicy U.S. government contracts that remind you why this name sits at the top of every defense investor’s watchlist.

But this isn’t just about momentum. Every deal General Dynamics signs — from submarines to IT systems — locks in years of steady revenue.

The company isn’t chasing hype; it’s stacking guaranteed work that will keep cash flowing no matter what the economy throws at it.

The Cash Keeps Coming

General Dynamics just landed a $1.5 billion contract to modernize the U.S. Strategic Command’s IT systems and another $600 million to keep the Navy’s submarine program running full steam.

These long-term wins are like annuities: slow, steady, and ridiculously reliable.

You don’t get many stocks that balance this kind of visibility with innovation.

From cybersecurity to shipbuilding, the company’s bench is deep and built to deliver. If you want predictability with upside, this is the model.

Why This Rally Still Has Fuel

Sure, the stock’s sitting at an all-time high, but there’s still room on the runway.

With a record backlog topping $100 billion, new jets rolling out, and defense budgets rising globally.

You don’t need to be an insider to see it: when a company keeps cashing billion-dollar checks while adding new growth engines, that’s a story you want to stay strapped into.

👉 Click here to get our closing report to your cell for free!

Trilogy Metals Inc [TMQ] $6.50 (+211.00%)

Trilogy Metals more than tripled after the Trump administration took a 10% equity stake and greenlit road access to its critical mineral project in Alaska.

Spruce Biosciences Inc [SPRB] $184.00 (+41.10%)

Spruce Biosciences extended its rally after securing FDA Breakthrough status for its Sanfilippo B treatment, fueling hopes for the first approved therapy for the rare neurodegenerative disorder.

Lexeo Therapeutics Inc [LXEO] $8.34 (+28.90%)

Lexeo climbed after revealing positive preliminary results for its Friedreich ataxia gene therapy and announcing the FDA is open to an accelerated approval path via pooled trial data.

Boqii Holding [BQ] $12.00 (-25.00%)

Boqii plunged after briefly spiking to over $40, as traders dumped shares amid the company’s denial of any material developments behind the wild rally.

SANUWAVE Health Inc [SNWV] $32.01 (-21.58%)

SANUWAVE fell despite record Q3 sales after the company missed revenue guidance and slashed its full-year outlook due to industry uncertainty.

Aehr Test Systems [AEHR] $26.15 (-17.38%)

Aehr tumbled as investors looked past the earnings “beat,” focusing instead on shrinking sales, weak bookings, and a swing to GAAP losses.

Elon Musk. Bill Gates. Jeff Bezos. Google. Even Robert Downey Jr.

They all put their money into energy storage. Why? Because without batteries, the clean energy future falls apart.

Musk himself said Tesla’s energy business will grow bigger than its car business. And last year proved it. Tesla deployed 31.4 GWh of storage and generated more than $10 billion in revenue.

But here is the thing. Tesla, Enphase, and Generac are already billion-dollar names. For everyday investors, the real upside is gone.

The real opportunity lies in a small US battery stock trading at just $177 million. Yet it is growing like wildfire. Revenue has more than tripled in a single year. Government programs already back its systems. And institutional investors like Vanguard and Fidelity have taken stakes.

Meanwhile, the macro winds could not be stronger. The US storage market is racing toward $465 billion by 2030. Electricity bills are climbing 6% to 8% every few years. Trump’s tariffs will slam imports with 34% penalties, but this small stock’s US and Austrian supply chain keeps it safe.

This is the kind of setup where billionaires quietly load up first. The question is whether you will get in before Wall Street notices.

See why investors are watching this deal.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.